EMA Authorised: Scintimun (besilesomab) — Telix Innovations

View source ↗

Summary

The European Medicines Agency authorised Scintimun (besilesomab) for radionuclide imaging to aid in diagnosing osteomyelitis. Telix Innovations is the marketing…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteomyelitis

Drugs mentioned

• Scintimun (besilesomab)

Snippet

Status: Authorised. Therapeutic area: Osteomyelitis;Radionuclide Imaging. MAH: Telix Innovations. Decision date: 17/03/2025